Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone.

ABSTRACT:

Background

Bone metastasis is a common consequence of advanced prostate cancer. Bisphosphonates can be used to manage symptoms, but there are currently no curative treatments available. Altered tumour cell glycosylation is a hallmark of cancer and is an important driver of a malignant phenotype. In prostate cancer, the sialyltransferase ST6GAL1 is upregulated, and studies show ST6GAL1-mediated aberrant sialylation of N-glycans promotes prostate tumour growth and disease progression.

Methods

Here, we monitor ST6GAL1 in tumour and serum samples from men with aggressive prostate cancer and using in vitro and in vivo models we investigate the role of ST6GAL1 in prostate cancer bone metastasis.

Findings

ST6GAL1 is upregulated in patients with prostate cancer with tumours t

SUBMITTER: Hodgson K 

PROVIDER: S-EPMC11134892 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature